[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sentinel-lymph-node-biopsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sentinel-lymph-node-biopsy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,77,119,156,189,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100570261","phase-3-no-axillary-surgical-treatment-in-clinically-lymph-node-negative-patients-on-ultrasonography-after-neoadjuvant-chemotherapy-100570261",false,"NCT06704945","No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy","No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy: A Prospective, Phase III Clinical Trial","Neo-NAUTILUS","Inclusion Criteria:\n\n* Women aged ≥19 years.\n* Histologically confirmed invasive breast carcinoma treated with neoadjuvant chemotherapy.\n* Clinical staging prior to NAC: cT1-3, cN0, M0 (AJCC 8th Edition).\n* If pre-NAC staging is cT1-3, cN1, M0, must meet the following criteria:\n\n  1. HER2-positive or triple-negative breast cancer (TNBC).\n  2. At least 30% reduction in tumor size on MRI after NAC (comparing pre- and post-NAC MRI).\n* Negative axillary lymph node status on ultrasound after NAC.\n* Planned for breast-conserving surgery with completed neoadjuvant chemotherapy (at least half the planned regimen must be completed).\n* ECOG performance status of 0-2.\n* Signed written informed consent before enrollment.\n\nExclusion Criteria:\n\n* History of any cancer within the past 5 years.\n* Bilateral breast cancer.\n* Patients requiring mastectomy.\n* Tumor size \\>5 cm after NAC.\n* Male breast cancer.\n* Pregnant or breastfeeding women.\n* Inability to understand and complete questionnaires.","FEMALE","19 Years",{"count":20,"type":21},464,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","NEO-NAUTILUS is a prospective, multicenter, randomized phase III clinical trial to evaluate whether omitting axillary lymph node surgery (ALND or SLNB) in clinically lymph node-negative breast cancer patients after neoadjuvant chemotherapy is non-inferior to performing SLNB in terms of 5-year disease-free survival.",[27,28,29],"Breast Cancer","Neoadjuvant Therapy","Sentinel Lymph Node Biopsy",[31,32,33,34,35],"Omission of axillary surgery after neoadjuvant chemotherapy","Breast cancer","Neoadjuvant chemotherapy","De-escalation","Omission of surgery","RECRUITING","2026-01-26",{"date":39,"type":40},"2026-01-28","ACTUAL",{"date":42,"type":40},"2025-06-04",{"date":44,"type":21},"2034-12-31",{"name":46,"class":47},"Seoul National University Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100618984","does-ultrasound-guidance-axillary-incision-improve-sentinel-lymph-node-detection-in-breast-cancer-100618984","NCT07338721","Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer?","Does Using Ultrasound Guidance During Axillary Incision Improve Sentinel Lymph Node Detection Compared to Standard Methods in Breast Cancer Patients?","Inclusion Criteria:\n\n* \\* Patients with clinical stage T1-T3 disease (tumor ≤5 cm), pN0-pN1 (one to three regional lymph nodes with micrometastases or metastases), and M0 (no distant metastasis) are eligible. Post-neoadjuvant yT1-T3, yN0-yN1, and M0 status are also eligible. All patients are undergoing axillary staging.\n* Clinically negative axilla\n* Written informed consent must be obtained prior to inclusio\n\nExclusion Criteria:\n\n* Younger than 18 years\n* Previous breast malignancy\n* Pregnancy\n* Pre-operative diagnosis of axillary lymph node metastases\n* The presence of multiple clinically involved or suspicious lymph nodes\n* Unable or unwilling to provide informed consent.","18 Years",{"count":58,"type":21},40,"2 Weeks","OBSERVATIONAL","This single-center randomized controlled trial evaluates whether detecting the first lymph node at the axillary entrance with ultrasound guidance, followed by a targeted axillary incision over the pencil-marked projection, improves sentinel lymph node identification compared to the conventional axillary hairline landmark. The study hypothesizes that this technique enables a smaller incision, minimizes tissue dissection, and reduces operative time.",[63,29],"Breast Carcinoma",[32,65,29,66],"Axilla","Ultrasonography","2026-01-14",{"date":69,"type":40},"2026-01-15",{"date":71,"type":40},"2026-01-01",{"date":73,"type":21},"2026-06-15",{"name":75,"class":76},"Antalya Training and Research Hospital","OTHER_GOV",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":85,"minAge":56,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":103,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":48},"100566245","sentinel-node-and-organ-sparing-surgery-in-stage-i-colon-carcinoma-100566245","NCT06652672","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma (SENTRY Trial)","SENTRY","Inclusion Criteria:\n\n* Oral and written informed consent (IC)\n* Aged 18 years and older\n* Fit for both organ-sparing surgery and colectomy\n* Pathologically confirmed T1-2 adenocarcinoma of the colon following R0, R1, or Rx endoscopic resection with an estimated LNM risk \\>15% (Table 5.2.2. in module 5.2 of the Dutch CRC guideline); or a lesion macroscopically suspected to be (deep-invasive) T1 colon cancer, measuring \\\u003C40 mm, for which wedge resection is considered the most suitable local resection technique as recommended by the MDT\n* The resection scar after local excision is expected to be clearly recognized at endoscopy, either by a tattoo or by detecting a scar in the colorectal segment where no other polypectomies were performed\n* Lesion located \\>25cm from the anus based on endoscopic measurement, or above sigmoid take-off\n\nExclusion Criteria:\n\n* Patients who opt for active follow-up instead of surgery following shared decision-making\n* Distant metastasis\n* Lynch syndrome\n* Another active malignancy requiring palliative treatment at the time of colon cancer diagnosis\n* Previous colorectal cancer within the last 5 years\n* Tumours that comprised \\>50% of the colon circumference before resection\n* Tumours involving the ileocaecal valve\n* Pregnancy, lactation or a planned pregnancy during the course of the study\n* Known allergy to any of the compounds used for SLN identification (ICG, Iodine or Sodium iodide)\n* Previous colonic surgery (excluding appendectomy)\n* Contra-indication for laparoscopic or robotic surgery\n* Severe kidney- or liver failure\n* Hyperthyroidism or an autonomously functioning thyroid adenoma","ALL",{"count":87,"type":21},341,[89],"NA","The aim of this study is to reduce the need for colectomy and its' associated morbidity and mortality in patients with pT1-2 colon carcinoma after endoscopic resection and an estimated lymph node metastasis (LNM) risk of \\>15%, or with macroscopically suspected T1 tumors, by performing an endoscopic-assisted laparoscopic\u002Frobotic wedge resection of the tumor or scar, along with sentinel node (SLN) biopsy using indocyanine green (ICG). This intervention will be compared to the standard-of-care segmental resection using a partially randomized patient preference design. The primary outcome is the 3-year recurrence rate.",[92,93,94,29,95,96,97,98,99,100,101,102],"Colon Cancer","Colon Adenocarcinoma","Sentinel Lymph Node","Colon Neoplasms","Colon Neoplasm","Fluorescence","Fluorescence Guided Surgery","Fluorescence Laparoscopy","Fluorescence-guided Resection","Colon Surgery","Indocyanine Green (ICG)",[104,97,105,106,107,108,109],"Colon cancer","Sentinel lymph node","Indocyanine green (ICG)","Organ sparing surgery","Organ preserving surgery","Local resection","2025-11-17",{"date":112,"type":40},"2025-11-20",{"date":114,"type":40},"2024-12-12",{"date":116,"type":21},"2032-12-12",{"name":118,"class":47},"Meander Medical Center",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":85,"minAge":56,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":138,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100498763","sentinel-node-biopsy-versus-limited-elective-neck-dissection-in-early-cancers-of-oral-cavity-node-negative-100498763","NCT05774483","Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative","Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative (SECOND N0): Non-inferiority Phase III Trial","SECOND N0","Inclusion Criteria:\n\n1. Age \\>18 years of age\n2. Biopsy-proven invasive squamous cell carcinoma involving the site tongue and buccal mucosa\n3. T1 and T2 lesions as per AJCC TNM 8 edition\n4. Clinicoradiologically node negative\n5. Amenable to per oral excision\n6. Treatment naïve\n7. No other site of malignancy\n\nExclusion Criteria:\n\n1. Previous surgery in the head and neck region,\n2. Upper alveolar or palatal lesions\n3. Large heterogeneous leukoplakia or other premalignant lesions\n4. Previous malignancy in the head and neck region\n5. Patients requiring the free flap reconstruction","80 Years",{"count":129,"type":21},508,[89],"The goal of this clinical trial is to compare the survival outcomes, morbidity and cost-effectiveness of sentinel node biopsy versus limited elective neck dissection in node-negative early oral cancers.\n\nThe main questions it aims to answer are:\n\n* Survival outcomes\n* Morbidity outcomes\n* Cost-effectiveness\n\nParticipants will either undergo sentinel node biopsy followed by completion neck dissection if sentinel node is reported to be metastatic (SNB) or limited elective neck dissection where level IIb will be cleared only if level IIa is metastatic (limited END). The study will compare the outcomes in the two cohorts.",[133,134,135,136,29,137,94],"Mouth Neoplasms","Oral Cancers","Oral Squamous Cell Carcinoma (OSCC)","Oral Squamous Cell Carcinomas","Sentinel Lymph Node Biopsy (SLNB)",[139,140,141,142,143,144,145],"mouth neoplasms","neck dissection","sentinel lymph node biopsy","survival","morbidity","oral cancers","oral squamous cell carcinoma","2025-07-14",{"date":148,"type":40},"2025-07-17",{"date":150,"type":40},"2025-04-16",{"date":152,"type":21},"2034-04",{"name":154,"class":76},"Tata Memorial Hospital",3,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":173,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":48},"100583021","comparison-of-transvaginal-paracervical-and-transperitoneal-approaches-in-lymphadenectomy-during-v-notes-surgery-for-patients-diagnosed-with-endometrial-cancer-100583021","NCT06870903","Comparison of Transvaginal Paracervical and Transperitoneal Approaches in Lymphadenectomy During v-NOTES Surgery for Patients Diagnosed With Endometrial Cancer","ENDONOTE","Patient Selection and Data Collection This study will be implemented in a single institution, Diyarbakır Gazi Yaşargil Training and Research Hospital, which functions as a tertiary cancer treatment facility.\n\nBetween March 2025 and December 2025, patients with newly diagnosed clinical early stage (FIGO 2023 stages 1 and 2) endometrial cancer who will be treated with laparoscopic surgical staging with SLN mapping at our institution will be randomized into groups. The research procedure has been approved by the ethics committee\u002Finstitutional review board of Diyarbakır Gazi Yaşargil Training and Research Hospital and informed consent signed by the patient will be included in each table reviewed.\n\nEligible participants will be required to give informed consent to participate in the study.\n\nInclusion criteria will include\n\n* Participants whose endometrial biopsy resulted in endometrial cancer and whose disease will be detected limited to the uterus using imaging modalities (computed tomography \\[CT\\], magnetic resonance imaging or Fluorine-18 fluorodeoxyglucose positron emission tomography\u002FCT)\n* Absence of synchronous malignancies.\n* No neoadjuvant treatment before surgical intervention.\n\nExclusion criteria will include:\n\n* Contraindications to using methylene blue dye or contraindications to the vNOTES procedure.\n* Patients who have had previous malignancy surgery.\n* Severe, deeply penetrating endometriosis or enlarged uterus that may require forced vaginal extraction\n* Receiving neodajuvant therapy","85 Years",{"count":165,"type":21},52,[89],"The aim of this study is to compare two types of lymphadenectomy (transperitoneal vs. paracervical) during the lymphadenectomy phase of endometrial cancer staging surgery performed using V-NOTES, a new and advanced technique. This study seeks to optimize the V-NOTES technique for endometrial cancer staging. This randomized, prospective, controlled study will include patients diagnosed with endometrial cancer via histology, following physical examination and imaging, and who are electively scheduled for the V-NOTES endometrial cancer staging procedure. Patients will be randomized into two groups: the transvaginal paracervical lymphadenectomy group and the transperitoneal lymphadenectomy group. The parameters related with surgical and functional outcomes will be compared in both groups.",[169,170,29,171,172],"Endometrial Cancer","Lymphadenectomy","Minimally Invasive Surgical Procedures","Natural Orifice Transluminal Endoscopic Surgery",[174,175,176,177,178,179],"endometrial cancer","V-NOTES","lymphadenectomy","sentinel lymph node","transperitoneal","extraperitoneal","2025-03-17",{"date":182,"type":40},"2025-03-20",{"date":184,"type":40},"2025-03-15",{"date":186,"type":21},"2026-03-01",{"name":188,"class":47},"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":85,"minAge":56,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":48},"100555903","axillary-sentinel-lymph-node-biopsy-after-neoadjuvant-chemotherapy-in-patients-with-initial-cn1-breast-cancer-100555903","NCT06518135","Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer","Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer: a Prospective, Multicenter, Single Arm, Real World Study","Inclusion Criteria:\n\n1. Patients With ECOG Score 0-1 Points\n2. Patients With Breast Cancer Stage cT1-3N1M0 (According to AJCC Version 7) Pathological Diagnosis of Ipsilateral Axillary Lymph Node Metastasis in Patients With Invasive Breast Cancer\n3. Patients With Abnormal Axillary Lymph Nodes ≤ 3 Detected by Imaging Examination\n4. Patients With Effective Neoadjuvant Therapy (CR+PR)\n5. Patients With Clinical Axillary Negative ycN0 After Neoadjuvant Therapy\n6. Patients Without Prior History of Ipsilateral Axillary Surgery and Radiation Therapy\n7. Patients Without Previous History of Ipsilateral Breast Cancer (Including Carcinoma in Situ)\n8. Patients Without Obvious Contraindications for Surgery or Radiation Therapy\n9. No Other History of Malignant Tumors Within 5 Years From Enrollment in the Study\n10. Patients Who Participate in Other Clinical Trials at the Same Time and Are Judged by the Researchers Not to Affect the Study Protocol Can be Enrolled Normally\n11. The patient voluntarily joined this study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Stage IV (metastatic) breast cancer；\n2. Simultaneous double breast cancer；\n3. Baseline cT4;\n4. Baseline cN2-3\n5. gestation\n6. There are contraindications for SLNB;\n7. Suffering from serious comorbidities or other comorbidities that may interfere with the planned treatment, or any other circumstances in which the researcher deems the patient unsuitable to participate in this study","70 Years",{"count":129,"type":21},"SLNB has been recommended by domestic and foreign guidelines for patients with initial cN1 and NAC descending to ycN0. However, the best technical path is still not very clear at present, and the long-term tumor safety data is still insufficient. Therefore, it is necessary to further explore the optimal technical pathway and long-term tumor safety for SLNB in patients with initial cN1 and NAC downgrading to ycN0 in the real world.This study will evaluate the optimized technical pathway and long-term tumor safety of SLNB in patients with initial cN1 and NAC downgrading to ycN0 in real-world studies.",[29],[201],"Axillary sentinel lymph node biopsy",{"date":203,"type":40},"2024-12-17",{"date":205,"type":40},"2024-04-30",{"date":207,"type":21},"2028-03-31",{"name":209,"class":76},"Henan Cancer Hospital",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":220,"conditions":221,"keywords":230,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":48},"100393503","the-role-of-micrometastasis-and-isolated-tumor-cells-itcs-in-endometrial-and-cervical-cancer-a-multicenter-study-100393503","NCT04403867","The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.","The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Uterine Cancers (Endometrial\u002FCervical) Submitted to Sentinel Lymph Nodes (SLN) Procedure: an Observational Study","ITCMicroUtCa","Inclusion Criteria:\n\n* Early stage endometrial cancer scheduled for SLN procedure\n* Early stage cervical cancer scheduled for SLN procedure\n* Pathological evaluation of SLNs with standard ultra-staging or one-step nucleic acid amplification (OSNA) for the detection of metastasis\n* Presence of lymph nodes metastasis (macrometastasis or low volume disease \\[micrometastasis and isolated tumor cells\\])\n\nExclusion Criteria:\n\n* Previous (\\\u003C5 years) or concomitant malignancy other than non-melanoma skin cancer\n* Advanced\u002Fmetastatic endometrial cancer\n* Locally advanced\u002Fmetastatic cervical cancer",{"count":219,"type":21},500,"The role of small-volume lymph node disease (ITC and micro metastases) among patients with endometrial or cervical cancer submitted to sentinel node (SLN) procedure is not clearly defined.\n\nThis study was designed to create a dataset of patients with lymph nodal disease. Data on type and volume of lymph nodal disease, therapeutic choices and oncological outcomes (DFS, OS, recurrence rate) will be collected and analyzed.\n\nThis will allow to define the groups of patients who may need or for whom it can be avoided any adjuvant treatment on the basis of lymph node status.",[169,222,94,223,29,224,225,226,227,228,229],"Cervical Cancer","Micrometastasis","Endometrium Tumor","Endometrial Neoplasms","Cervical Neoplasm","Cervical Tumor","Lymph Node Metastases","Lymph Node Disease",[174,231,177,232,142,233,234,235,236,237,238,239],"cervical cancer","low volume disease","recurrence rate","adjuvant therapy","micrometastases","isolated tumor cell","macrometastases","ultrastaging","one-step nucleic acid amplification (OSNA)","2022-08-15",{"date":242,"type":40},"2022-08-17",{"date":244,"type":40},"2020-01-02",{"date":246,"type":21},"2027-01",{"name":248,"class":47},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"]